ValenTx is a technology company.
ValenTx has raised $22.0M across 1 funding round.
ValenTx has raised $22.0M in total across 1 funding round.
ValenTx has raised $22.0M in total across 1 funding round.
ValenTx's investors include Aisling Capital, SV Health Investors.
ValenTx is an early-stage medical device company that developed a non-surgical, implantable therapy aimed at treating morbid obesity and Type II Diabetes.[1][2][4] The therapy demonstrated significant efficacy in human clinical trials, targeting patients with these conditions through a minimally invasive approach.[1][2][5] Founded in 2002 and headquartered in Maple Grove, Minnesota, the company raised approximately $49.31M across funding rounds up to Series C-II but ultimately ceased operations, marked as "Dead" in industry profiles.[1][2]
ValenTx was founded in 2002 in Maple Grove, Minnesota, focusing from the outset on innovative medical devices for metabolic diseases.[1][2][4] Key details on specific founders are not available in profiles, but the company quickly advanced to clinical trials, generating strong efficacy data for its implantable therapy.[1][2] It expanded operations aggressively to support broader therapy applications, achieving revenue around $5M and employing about 6-9 people at its peak, with Jon Germain listed as CEO.[1][2] Early traction came from successful human trials, but despite $24.4M-$49.31M in funding, the company shut down post-Series C-II.[1][2]
ValenTx rode the early 2000s wave of minimally invasive medical devices, capitalizing on rising obesity and diabetes prevalence amid demands for non-surgical alternatives to bariatric procedures.[1][2][5] Timing aligned with advances in implantable tech and endovascular treatments, as seen in peers like Endologix for vascular issues, positioning ValenTx in the competitive obesity treatment space alongside firms like Apollo Endosurgery.[1] Though it ceased operations, its clinical data contributed to the ecosystem, influencing development-stage medtech for metabolic diseases and highlighting challenges in scaling early-stage devices amid funding and regulatory hurdles.[1][2]
ValenTx's story underscores the high-risk nature of medtech innovation, where promising clinical results did not sustain operations beyond Series C.[1][2] With the company defunct, its technology may resurface through acquisitions or IP licensing in a market still hungry for obesity solutions amid ongoing GLP-1 drug booms and device hybrids. Trends like AI-driven personalization and outpatient procedures could revive similar implants, but ValenTx itself offers no active path forward—its legacy lies in trial data advancing the non-surgical obesity tech frontier.[1][2]
ValenTx has raised $22.0M across 1 funding round. Most recently, it raised $22.0M Series B in September 2009.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2009 | $22.0M Series B | Aisling Capital, SV Health Investors |